What a cool idea

Over 70,000 patients in the US are treated annually with chemotherapeutics such as Platinum, Etoposide, Irinotecan. 70% of these patients become resistant to treatment within two years.

Galatea is creating a novel medicine that reverses this chemo-resistance, potentially increasing the survival of patients with lung and ovarian cancer.

Nearly a third of advanced lung cancers overexpress NRF2, a protein that drives cell survival and resistance to therapy. Many of these cancers require NRF2 expression for survival.

Ganymede is developing NRF2 degraders to treat NRF2-dependent cancers.

.

.

The wide adoption of CAR T therapies has been prevented by cost ($500K/patient) and complexity (2 weeks in a GMP-manufacturing facility).

Persistence reduces the time and cost of CAR T therapies by creating synthetic lymph nodes that are made outside the patient and then implanted using a minimally invasive procedure.

New technologies are changing the standard of care for glioblastoma and lung cancer treatment.

Pulsar is developing small molecule drugs to synergize with these new technologies to dramatically increase survival in patients with certain aggressive cancers.

Nearly 4% of metastatic cancers mutate a key component of the cohesin complex, making these cancers entirely dependent on residual cohesin complex function for survival.

Artemis is creating small molecules that target this unique vulnerability to treat cancers with particular mutations of the cohesin complex.

Imagine drugs engineered to accumulate at sites of disease to exert tissue-selective biology. Cavalry has created medicines that target the growth plate, muscle fibers, and secretory glands.

Cavalry expects to have two pIND meetings with the FDA in 2024, with one drug entering the clinic in 2025 and a second in 2026.